Postdoctoral Research Fellow
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
I am currently a Cancer Council SA Beat Cancer Early Career Research Fellow in the Myeloma Research Laboratory, Adelaide Medical School, University of Adelaide, based at the South Australian Health and Medical Research Institute (SAHMRI), Cancer Theme.
My PhD research centred on characterising the off-target effects of tyrosine kinase inhibitors on bone metabolism and skeletal growth in chronic myeloid leukaemia. My current research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma.
My current research interests involve elucidating the molecular and cellular mechanisms responsible for the disease progression in the bone marrow cancer multiple myeloma. Myeloma is the second most common blood cancer, responsible for approximately 80,000 deaths per year, world-wide. While significant advances in myeloma treatment over the past decade have greatly improved survival rates for multiple myeloma, almost all patients eventually relapse and succumb to their disease. My studies are primarily aimed at identifying those patients that do very poorly, surviving less than 2 years, and identifying tailored treatments for this group of patients.
The progression and relapse of myeloma tumours is critically dependent on the ability of the myeloma tumour cells to disseminate to sites throughout the skeleton. In particular, previous studies have identified that those patients with highly disseminated disease at diagnosis do particularly poorly, leading to rapid disease progression and disease relapse. One of my primary research interests focuses on identifying the intrinsic and extrinsic factors involved in the recirculation and dissemination process in myeloma with the aim of developing therapeutic strategies that will prevent disease progression and overt relapse in these patients.
Current projects include:
• Identification of novel prognostic factors that identify patients at a high risk of disease progression in myeloma
• Investigation of the mechanisms controlling the dissemination of myeloma plasma cells, including hypoxia, chemokine receptors and N-cadherin
• Identification of novel therapeutic targets for the treatment of high-risk multiple myeloma
• Characterisation of the off-target effects of a class of leukaemia drugs, termed tyrosine kinase inhibitors, on bone metabolism and skeletal growth
Date Position Institution name 2020 Senior research fellow South Australian Health and Medical Research Institute 2018 Beat Cancer Early Career Research Fellow University of Adelaide, Adelaide 2017 - 2018 Post-doctoral Research Scientist University of Adelaide, Adelaide 2013 - 2016 Mary Overton Early Career Research Fellow SA Pathology 2012 - 2018 Affiliate Lecturer University of Adelaide 2012 - 2013 Multiple Myeloma Research Foundation Research Fellow SA Pathology 2010 - 2012 Post-doctoral Research Scientist SA Pathology 2007 - 2010 Technical assistant (part time) SA Pathology 2005 - 2006 Research Assistant Prince of Wales Hospital
Date Institution name Country Title 2007 - 2010 University of Adelaide Australia PhD 2000 - 2004 University of New South Wales Australia BMedSci (Hons)
Year Citation 2017 Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2 alpha Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2014 Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY. 2013 Noll, J., Williams, S., Vandyke, K., Kok, C., & Zannettino, A. (2013). IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 GENE EXPRESSION IN A MURINE MODEL OF MYELOMA AND MYELOMA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 316). FERRATA STORTI FOUNDATION. 2008 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel (TM)) Inhibits Oteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY.
Year Citation 2019 Opperman, K., Vandyke, K., Psaltis, P., Croucher, P., Noll, J., & Zannettino, A. (2019). Macrophages as a potential therapeutic target: Clodronate-liposome treatment inhibits multiple myeloma tumour establishment in vivo. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
2008 Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley.
|2019-2022||CoI||Strategic Ecosystem Research Partnerships||Leukaemia Foundation||AUD$596,198|
|2019 - 2020||CIA||Cancer Australia Priority-driven Young Investigator Grant||Cancer Australia/Cure Cancer Australia/Leukaemia Foundation||AUD$198,596|
|2017-2018||CIA||Cancer Australia Priority-driven Young Investigator Grant||Cure Cancer Australia||AUD$199,454|
|2016||CIA||Project Grant||Royal Adelaide Hospital Contributing Haematologists' Committee||AUD$25,000|
|2016||CIE||Project Grant||Royal Adelaide Hospital Research Fund||AUD$50,000|
|2018-2021||Beat Cancer Early Career Cancer Research Fellowship||Cancer Council SA||AUD$240,000|
|2013-2015||Mary Overton Early Career Fellowship||Royal Adelaide Hospital||AUD$252,000|
|2013-2015||Veronika Sacco Early Career Fellowship||Florey Medical Research Foundation||AUD$222,003|
|2011||MMRF Research Fellow Award||Multiple Myeloma Research Foundation (USA)||AUD$74,146|
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2020 Co-Supervisor Changes in the bone marrow microenvironment with progression to multiple myeloma Doctor of Philosophy Doctorate Full Time Miss Laura Joy Trainor 2020 Co-Supervisor Identification of novel mechanisms that drive the dissemination of multiple myeloma tumour cells Doctor of Philosophy Doctorate Full Time Miss Hayley Bridget Parkinson 2020 Co-Supervisor A novel nanoparticle-based approach for optimising the treatment of Multiple Myeloma Doctor of Philosophy Doctorate Part Time Ms Sadia Munir 2019 Co-Supervisor The Yin and Yang of Myeloma Development: The Role of the Bone Marrow Microenvironment in Plasma Cell Dormancy and Activation Doctor of Philosophy Doctorate Full Time Miss Natalya Plakhova 2019 Co-Supervisor Investigating the Role of Resident Bone Macrophages in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mrs Khatora Shanae Opperman
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2017 - 2020 Principal Supervisor CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance Doctor of Philosophy Doctorate Full Time Miss Mara Natasha Zeissig 2013 - 2017 Co-Supervisor The Role of TWIST1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Chee Man Cheong 2012 - 2018 Co-Supervisor N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mr Krzysztof Mrozik
Date Role Committee Institution Country 2015 - ongoing Member Women's and Children's Hospital Foundation Research Grants Committee — — 2014 - ongoing Member Australian Society for Medical Research SA Committee — —
Date Role Membership Country 2015 - ongoing — Haematology Society of Australia and New Zealand — 2014 - ongoing Member Australian Society for Medical Research —
Connect With Me